AstraZeneca's Atacand Adds ACE Inhibitor Combo Claim For Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Angiotensin receptor blocker is the first in its class to gain the indication. FDA's approval is in line with the Cardio-Renal Advisory Committee's unanimous recommendation in February.